Related by context. All words. (Click for frequent words.) 69 immunotherapy 69 immunotherapeutics 66 cancer immunotherapy 65 immunotherapeutic 65 proteasome inhibitors 64 therapies 64 monoclonal antibodies 64 MEK inhibitors 63 oncolytic viruses 63 kinase inhibitors 62 cancer immunotherapies 62 therapeutics 62 anticancer agents 62 anticancer therapies 62 antisense drugs 62 small molecule inhibitors 62 antiviral therapies 62 therapeutic monoclonal antibodies 61 chemotherapeutics 61 chemotherapeutic agents 61 anticancer drugs 61 protein therapeutics 61 antiviral therapeutics 61 RNAi therapeutic 61 tumor antigen 61 cancer therapeutics 61 mAbs 60 tumor antigens 60 siRNA therapeutics 60 PI3K inhibitors 60 novel peptide 60 antisense oligonucleotides 60 hematological cancers 60 molecularly targeted 60 monoclonal antibodies MAbs 60 personalized immunotherapy 60 antiviral compounds 60 oncolytic virus 60 chemotherapies 60 humanized antibodies 59 oncolytic 59 TLR8 59 anticancer therapeutics 59 therapeutic antibodies 59 PARP inhibitors 59 MAbs 59 humanized monoclonal antibodies 59 therapeutic antibody 59 VitiGam 59 Ceflatonin 59 oncology therapeutics 59 TLR9 agonist 59 BiTE antibody 59 fusion proteins 59 A3 adenosine receptor 59 novel immunotherapies 59 tyrosine kinase inhibitors 59 JAK inhibitors 59 MyVax R 59 OncoVEX 59 nanoviricides 59 imatinib Gleevec 59 NovaBay Aganocide compounds 59 DCVax 59 immune modulators 58 DNA plasmids 58 peptide antigens 58 Monoclonal antibodies 58 targeting CD# 58 myeloproliferative disorders 58 small molecule 58 tyrosine kinase inhibitor 58 chemotherapeutic 58 M2 subunit 58 HDAC inhibitors 58 antisense 58 EGFR inhibitors 58 prodrugs 58 monoclonal antibody 58 humanized anti 58 biologic therapies 58 cellular immunotherapy 58 lentiviral vector 58 mda 7 58 JAK3 58 TREANDA 58 polymerase inhibitors 58 antibody therapeutics 58 bevacizumab Avastin ® 58 depsipeptide 58 immunotoxins 58 CXCR4 receptor 57 chemotherapeutic drugs 57 investigational therapies 57 TRAIL receptor antibodies 57 Hsp# inhibition 57 Gleevec imatinib mesylate 57 RNAi therapeutic targeting 57 imatinib Gleevec ® 57 anticancer therapy 57 investigational compounds 57 UsiRNAs 57 immunomodulators 57 JAK1 57 antisense drug 57 Xanafide 57 BCR ABL inhibitors 57 Gleevec resistant 57 hemorrhagic fever viruses 57 neuroendocrine cancers 57 HuLuc# 57 immunomodulator 57 BiovaxID 57 IMA# 57 novel antibody therapeutics 57 proteasome inhibitor 57 NEUGENE 57 nanomedicines 57 HSP# inhibitor 57 bioartificial liver 57 autoimmune diseases 57 selective inhibition 57 DOS# 57 Curaxin 57 Immunotherapy 57 Listeria vaccine 57 humanized antibody 57 investigational monoclonal antibody 57 solid tumors 57 delta isoform 57 prophylactic vaccine 57 anticancer compounds 56 monoclonal antibody therapies 56 Nanobody 56 TLR9 56 PXD# 56 predictive biomarkers 56 antigens 56 taxanes 56 hematological malignancies 56 DXL# 56 liposomal delivery 56 HGS ETR1 56 FGFR 56 huC# DM4 56 interferon lambda 56 hematologic malignancies 56 immunological diseases 56 NF kB pathway 56 Tarvacin 56 RNAi therapeutics 56 chemotherapeutic drug 56 molecular biomarkers 56 TLR9 agonists 56 antibody 56 siRNA compounds 56 Th2 cells 56 Allovectin 7 ® 56 GammaCan 56 GAP #B# 56 PEGylated 56 erlotinib Tarceva ® 56 transfection reagents 56 receptor tyrosine kinase inhibitor 56 prophylactic vaccines 56 DCVax R 56 MAbs targeting 56 viral vectors 56 disease modifying 56 adenovector 56 AEG# 56 NexACT 56 BRAF inhibitor 56 synthetic retinoid 56 immunomodulatory 56 Symadex 56 milatuzumab 56 biologic therapeutics 56 NASDAQ OPXA 56 Personalized Immunotherapy 56 GRN#L 56 GRNVAC1 56 OMP #M# 56 IGF 1R 56 EGFr 56 epigenetic therapies 56 chemically modified siRNA 56 electroporation 56 Rituxan rituximab 56 ENMD # 56 siRNA delivery 56 antibodies 55 monoclonal 55 Hsp# inhibitors 55 peptides 55 cytotoxin 55 TKIs 55 Azedra 55 small molecule agonists 55 siRNA therapeutic 55 stem cell therapeutics 55 EphA2 55 Scancell 55 pertuzumab 55 interferon IFN 55 FLT3 55 theranostics 55 Allovectin 7 55 HDACi 55 protein kinase inhibitor 55 IGF IR 55 ganetespib 55 IAP inhibitors 55 JVRS 55 vascular disrupting agents 55 relapsed leukemia 55 Viprovex TM 55 rxRNA compounds 55 Sym# 55 DiLA2 55 liposomal 55 monoclonal antibody mAb 55 monoclonal antibody therapeutics 55 NPC 1C 55 selective kinase inhibitor 55 HDAC inhibitor 55 JAK2 inhibitors 55 CD# antibody [001] 55 HepaLife Technologies Inc. 55 preclinically 55 lupus nephritis 55 recombinant vaccines 55 signal transduction inhibitors 55 belinostat 55 anti angiogenic agents 55 immune modulation 55 Smac mimetics 55 exon skipping 55 prostone 55 immunosuppressive regimens 55 anticancer treatments 55 synergistic combinations 55 Alemtuzumab 55 antibody cytokine 55 HCV protease inhibitors 55 Talabostat 55 epithelial tumors 55 multitargeted 55 c MET 55 Proxinium TM 55 Atiprimod 55 immunotherapy treatments 55 Tranzyme 55 lentiviral vectors 55 oncology indications 55 DCVax Brain 55 Alocrest 55 OncoVEX GM CSF 55 Revimmune 55 Tarvacin TM 55 antiangiogenesis therapies 55 Panzem 55 polyclonal antibodies 55 drug conjugate 55 CBLC# 55 humanized monoclonal antibody 55 interferon alpha 55 OHR/AVR# 55 siRNA 55 voreloxin 55 IgG1 antibody 55 anticancer agent 55 ribonucleotide reductase clinically validated 55 cytotoxic agents 55 covalent drugs 55 RhuDex ® 55 therapeutic regimens 55 IL# PE 55 XmAb ® 55 Hedgehog signaling pathway 55 nanoviricide 55 Celator 55 RGB # 55 PORxin 55 Allovectin 7 R 55 myelofibrosis polycythemia vera 55 IAP inhibitor 55 EpCAM 54 enveloped viruses 54 cytotoxic 54 Fibroblast Growth Factor Receptor 54 BioVant 54 xenograft models 54 vorinostat 54 anti angiogenesis 54 multi kinase inhibitor 54 CD# monoclonal antibody 54 Fleximer 54 Aplidin 54 Epothilones 54 IMC A# 54 ErbB3 HER3 54 dermatology therapies 54 antisense compounds 54 chronic viral infections 54 rxRNA 54 epithelial cancers 54 VEGF inhibitors 54 Cylene 54 clinically validated targets 54 ZFPs 54 PKC# 54 Radilex 54 virotherapy 54 dependent cellular cytotoxicity 54 Nanobodies 54 cMET 54 Cancer Therapeutics 54 AAV2 54 AMPK activators 54 aptamer 54 INT# [002] 54 Pralatrexate 54 Hedgehog pathway 54 vaccines oncolytic virus 54 Locked Nucleic Acid 54 Nanobody ® 54 ALN PCS 54 nucleoside analogs 54 CTLA4 Ig 54 synthetic peptides 54 TPI ASM8 54 neutralizing antibodies 54 RNAi 54 Azixa 54 isoform selective 54 standard chemotherapy regimens 54 carbohydrate polymers 54 immunogens 54 kinase inhibitor 54 geldanamycin 54 angiogenesis inhibitors 54 anticoagulant reversing agent 54 immunoconjugate 54 chemotherapeutic regimens 54 HyperAcute 54 ALN VSP 54 radionuclide therapy 54 proliferative diseases 54 lymphomas 54 antisense therapies 54 glioblastoma multiforme GBM 54 biotherapy 54 DsiRNA 54 antibody therapies 54 PARP inhibitor 54 viral antigens 54 small molecule modulators 54 molecular assays 54 targeted antifolate 54 TRV# [001] 54 adenoviral 54 otelixizumab 54 Onconase 54 hyperthermia therapy 54 Corgentin 54 Pertuzumab 54 co stimulatory molecules 54 therapeutic monoclonal antibody 54 Marqibo 54 histone deacetylase inhibitors 54 TTR gene 54 ocular formulation 54 kidney urologic 54 immunotherapeutic approaches 54 regenerative medicine therapies 54 MLN# 54 taxol 54 DermaVir 54 TAFA# 54 p# inhibitors 54 Epiphany Biosciences 54 theranostic 54 YONDELIS 54 EGFR antibodies 54 tubulin binding 54 aptamers 54 targeted radiotherapeutic 54 selective immunoproteasome inhibitor 54 pDCs 54 Tumor Necrosis Factor 54 bispecific antibody 54 ProLindac 54 Gefitinib 54 recombinant antibodies 54 oncoproteins 54 SGLT2 54 sunitinib Sutent ® 54 myeloma cells 54 alkylating 54 cilengitide 54 molecularly targeted therapies 54 allosteric modulators 54 PEGylation technology 54 mTOR inhibitors 54 gastrin 54 vaccine adjuvant 54 intracellular signaling pathways 54 small molecule therapeutics 54 vinca alkaloids 54 novel RNAi therapeutics 54 BiTE 54 Th# cells 54 VEGF receptor 54 Tarmogen 54 dasatinib Sprycel 54 AKT inhibitor 54 OXi# 54 anti idiotype 54 trastuzumab Herceptin 53 ProNAi 53 MOZOBIL 53 NEUGENE antisense 53 adenovirus vector 53 Carfilzomib 53 Smac mimetic 53 chemokine receptors 53 LNP formulations 53 adult mesenchymal stem 53 alpha folate receptor 53 chemotherapy regimens 53 EndoTAG 53 immune modulatory 53 interferons 53 Novartis Gleevec 53 mertansine 53 CYC# 53 histone deacetylase HDAC 53 Zolinza 53 Factor VIIa 53 androgen receptor AR 53 novel peptides 53 MEK inhibitor 53 T#I [002] 53 telomerase inhibitor 53 PKCi 53 obatoclax 53 renin inhibitors 53 antibody fragment therapeutics 53 HepaLife 53 Intravenous CP 53 small molecule activators 53 Doxorubicin 53 OvaRex ® MAb 53 XmAb# 53 Blinatumomab 53 anti infective treatments 53 regenerative therapies 53 radiolabeled antibodies 53 biotherapeutics 53 mitogen activated ERK kinase 53 chemotherapeutic agent 53 erlotinib Tarceva 53 therapeutic peptide 53 antisense inhibitors 53 Cloretazine VNP#M 53 diseases fat malabsorption 53 AP# [003] 53 Therapeutic antibodies 53 TLR7 53 mAb 53 selective inhibitors 53 Dicer Substrate Technology 53 investigational humanized monoclonal antibody 53 VentiRx 53 iPSC 53 dasatinib Sprycel ® 53 Kevetrin 53 ixabepilone 53 PI3K/mTOR 53 Exelixis compounds 53 hedgehog pathway 53 Th2 cytokines 53 orally dosed 53 TRAIL receptor 53 rxRNA TM compounds 53 broadly neutralizing antibodies 53 viral vector 53 membrane receptors 53 AMN# [001] 53 TLR3 53 CYT# potent vascular disrupting 53 epothilones 53 CEQ# 53 TH# cells 53 small molecule defensin 53 Epitomics 53 MUC1 53 NEUGENE R 53 ASONEP 53 HQK 53 nucleoside analogues 53 HDAC inhibition 53 IRX 2 53 novel therapeutics 53 Insegia 53 Opexa Therapeutics Inc. 53 Transdrug ® nanoparticle 53 immunotoxin 53 immunological 53 Nanobodies ® 53 seliciclib 53 TLR agonists 53 protein kinase inhibitors 53 Bortezomib 53 INGN 53 metastatic melanoma 53 entinostat 53 polyclonal antibody 53 gefitinib Iressa 53 compound COTI 53 GPCR targets 53 PEG SN# 53 HAAH 53 Eg5 53 Hsp# inhibitor 53 TNFa 53 CD# expressing 53 myelofibrosis 53 oritavancin 53 TLR8 agonist 53 glioma cells 53 ActivX 53 Sphingomab 53 costimulatory 53 Preclinical studies suggest 53 brostallicin 53 PDGF receptor 53 short interfering RNA 53 cytotoxic T lymphocytes 53 anti CD# antibodies 53 intranasal delivery 53 immunotherapeutic vaccine 53 Cytolin ® 53 inhibit viral replication 53 IFN alpha 53 recurrent ovarian cancer 53 PNP inhibitor 53 Quinamed 53 ISF# 53 bevacizumab Avastin 53 #D#C# 53 Cellerant 53 CCX# 53 Omacetaxine 53 Novosom 53 molecularly targeted therapy 53 Nasdaq MITI biopharmaceutical 53 cytotoxics 53 metastatic renal cell carcinoma 53 MMAE 53 BAY #-# 53 anticancer 53 thalidomide Thalomid 53 Annamycin 53 pro angiogenic 53 CDDO Im 53 PI3 kinase 53 lipid nanoparticles 53 EGFR tyrosine kinase inhibitors 53 sapacitabine 53 G Protein Coupled 53 NXL# 53 telomerase activation 53 sigma receptors 53 diagnostic assays 53 effector function 53 AQ4N 53 Notch receptors 53 RNA antagonist 53 adaptive immunity 53 Amigal 53 angiogenesis inhibitor 53 Genentech Herceptin 53 EGFR HER 53 IL# PE#QQR 53 HDAC 53 MKC# MT 53 MT#/MEDI-# 53 taxane 53 Arimoclomol 53 Gemin X 53 NIC5 53 mimetics 53 BHT DNA 53 tkRNAi 53 vitro assay 53 LEX System 53 VEGF receptors 53 novel kinase inhibitors 53 metastatic kidney 53 immunomodulation 53 ALN TTR 53 telomerase therapeutic 52 antibody MAb 52 ACZ# 52 chemopreventive agents 52 accumulate preferentially 52 vinca alkaloid 52 Transfection Reagent 52 ZFP Therapeutic 52 neuroendocrine tumors 52 Homspera TM 52 glioblastoma 52 triphendiol 52 Abiraterone acetate 52 T DM1 52 ALN TTR# 52 biotherapies 52 PI3K inhibitor 52 TLR Therapeutics 52 LHRH antagonists 52 alpha interferon 52 hepatitis C viral infection 52 RNA interference RNAi therapeutics 52 DGAT1 inhibitors 52 antifungal agents 52 INCB# [001] 52 sodium glucose cotransporter 52 chronic lymphocytic leukemia CLL 52 TELCYTA TM TLK# 52 TELINTRA 52 oral antiviral 52 Valortim R 52 fusion inhibitor 52 protein kinases 52 Neugene 52 AAV vector 52 liposomal formulation 52 P#X# 52 MEK inhibitor RDEA# 52 drug ISA# 52 orally bioavailable 52 monoclonal antibody MAb 52 REOLYSIN ® 52 CD# CEA 52 RAV# 52 Phase #b/#a clinical 52 calcineurin inhibitors 52 5 HT4 receptor 52 KRAS mutant 52 Galectins 52 mucosal vaccines 52 immatics 52 viral diseases 52 tyrosine kinase inhibitors TKIs 52 HER2 receptor 52 LBH# 52 mapatumumab 52 bioactive lipids 52 telomerase inhibitors 52 preclinical studies 52 TG# [003] 52 OTCBB HPLF FWB HL1 52 bispecific 52 HepDirect R 52 oral proteasome inhibitor 52 organ transplant rejection 52 human parthenogenetic stem 52 Hybridon 52 mutational status 52 Janus kinase 52 immuno oncology 52 Clofarabine 52 Zybrestat 52 anti CD3 52 Virulizin ® 52 metastatic cancers 52 vidofludimus 52 PCK# 52 MVA BN R 52 Phylomer ® 52 immunoregulatory 52 pDNA vaccines 52 SERMs 52 antitumoral 52 ganaxolone 52 CD#L 52 enzastaurin 52 Herceptin trastuzumab 52 PNT# 52 anticancer compound 52 gene therapy 52 EndoTAGTM 1 52 decitabine 52 sPLA2 52 biologic therapy 52 BRAF inhibitors 52 Olaparib 52 anionic backbone 52 Angiolix 52 AKIP ™ 52 microRNA therapeutics 52 immune modulating 52 immune stimulatory 52 preclinical 52 stem cell therapies 52 MyVax 52 neuropilin 52 antagomirs 52 Vidofludimus 52 cytotoxic T 52 SCYNEXIS 52 antisense oligonucleotide 52 Calistoga Pharmaceuticals 52 EndoTAG TM 52 vitamin D analogs 52 Etubics 52 antitumor 52 aptamer therapeutics 52 lintuzumab 52 proliferative disorders 52 diagnostic biomarkers 52 rheumatoid arthritis multiple sclerosis 52 anti CD3 monoclonal 52 Campath alemtuzumab 52 Phenoxodiol 52 Cerashield 52 JAK2 inhibitor 52 Cloretazine 52 VLPs 52 Bendavia 52 recombinant vaccine 52 Dapagliflozin 52 HuCNS SC ® 52 targeted immunotherapies 52 BRAF kinase 52 ProMune 52 anti angiogenic drugs 52 KL4 surfactant 52 secretory diarrhea 52 amrubicin 52 hES cells 52 Litx 52 PLX cells 52 pediatric acute lymphoblastic 52 NeuroVax TM 52 superantigens 52 ATL# [001] 52 adoptive immunotherapy 52 alvespimycin 52 epitope 52 Semafore 52 olaparib 52 Gleevec imatinib 52 cetuximab Erbitux R 52 Sutent sunitinib 52 cytokine 52 Regado 52 Nasdaq HALO biopharmaceutical 52 apoptotic pathway 52 rBChE 52 molecular imaging radiopharmaceuticals 52 chronic myelogenous leukemia CML 52 Vorinostat 52 Seliciclib 52 antiviral therapy 52 AAV vectors 52 tramiprosate 52 ophthalmic diseases 52 Multimeric 52 talabostat 52 Charlesson 52 biotherapeutic 52 Altastaph 52 Paclitaxel 52 parthenogenetic stem cells 52 gamma secretase inhibitors 52 Nexavar ® 52 Interferon alpha 52 Synergy Pharmaceuticals 52 OvaRex R 52 Reolysin 52 Curaxins 52 immunoregulation 52 ErbB3 52 nicotinic alpha 7 52 demonstrated antitumor activity 52 DNAi 52 vascular disrupting agent 52 tyrosine kinases 52 ArQule Kinase Inhibitor Platform 52 Ii protein 52 Neuvenge 52 attach auristatin 52 BAL# [001] 52 EGFRvIII 52 Survivin antagonist 52 IFN gamma 52 tubulin inhibitor 52 C5aR 52 cell malignancies 52 kinase inhibition 52 Aurora kinase 52 ZFP TF 52 somatostatin analogue 52 Chemokine Therapeutics 52 vaccine adjuvants 52 Davunetide 52 nucleotide analogues 52 Immunogen 52 multikinase inhibitor 52 dacetuzumab 52 VaxInnate 52 novel immunomodulatory 52 nucleoside 52 Guanilib 52 anti angiogenic 52 Tarceva erlotinib 52 T#I mutant 52 L BLP# 52 Mitoxantrone 52 transgenic rats 52 Vandetanib 52 Nasdaq IMGN biotechnology 52 MDSCs 52 Archexin 52 induce apoptosis 52 TGF β 52 heavily pretreated 52 antigen CD# 52 p# inhibitor 52 AAG geldanamycin analog 51 resolvins 51 Epidermal Growth Factor Receptor 51 fluoropyrimidine 51 recombinant protein 51 PORxin TM 51 Nexavar sorafenib 51 CCR9 antagonist 51 photosensitizer 51 ErbB 51 DepoVax TM 51 synthetic peptide 51 Anthim 51 antibody mediated 51 anti CD# monoclonal 51 docetaxel Taxotere 51 dendritic cell 51 Jennerex 51 Sphingomab TM 51 specific lectin receptors 51 Vaxfectin TM 51 BRAF mutation 51 CMV vaccine 51 Curaxin CBLC# 51 imetelstat 51 NS4A 51 Aeolus Pharmaceuticals 51 intratumoral injection 51 radezolid 51 HDACs 51 cellular pathways 51 CR# vcMMAE 51 Fludara ® 51 EGFR pathway 51 IMGN# 51 Bezielle 51 MCSP respectively 51 Ebola vaccine 51 synthetic analogues 51 FGFR2 51 pancreatic cancers 51 therapeutic modalities 51 Adnectin 51 herpes simplex viruses 51 HCV protease 51 CB1 antagonists 51 haematopoietic 51 NY ESO 51 potent anticancer 51 XmAb 51 Lenocta 51 oncolytic virus therapies 51 histone deacetylase HDAC inhibitors 51 Advexin 51 TransMolecular 51 Tyrima 51 enzyme inhibitors 51 Stapled Peptide 51 antibody MT# 51 MyVax ® 51 fatty acid biosynthesis 51 NEUMUNE 51 triterpenoids 51 molecular abnormalities 51 glycosylated 51 leukemia AML 51 small molecule inhibitor 51 ProSavin 51 Tarvacin Anti Viral 51 HER2 positive metastatic breast 51 GM CSF 51 anti leukemic 51 hormone gastrin 51 CORT # 51 Maribavir 51 anidulafungin 51 dexpramipexole 51 immunosuppressive 51 PI3 kinase inhibitors 51 NTDDS 51 radiation sensitizer 51 CA4P 51 dAbs 51 Exherin TM 51 lumiliximab 51 Clavis Pharma 51 trastuzumab Herceptin ® 51 Achaogen 51 MUC1 protein 51 Sudhir Agrawal D.Phil 51 Cyclosert 51 PEGylation 51 MGCD# [001] 51 Pervasis 51 deacetylase inhibitors 51 retroviral vectors 51 antimicrobial compounds 51 Mpex 51 Vidaza ® 51 GBM tumors 51 SGLT2 inhibitors 51 Dr. Aiping Young 51 cytotoxic chemotherapy 51 MGd 51 thiazolides 51 GeoVax vaccine 51 leukemic cells 51 biomarker discovery 51 Sapacitabine 51 chronic myeloid leukemia CML 51 PLK1 SNALP 51 trastuzumab DM1 T DM1 51 Everolimus 51 Vaxfectin 51 Cabazitaxel 51 gastrointestinal stromal tumors 51 genetic biomarkers 51 Pazopanib 51 PARP inhibition 51 prostate cancer antigen prostatic 51 transfection reagent 51 DNA methylation biomarkers 51 relapsed multiple myeloma 51 LymphoStat B belimumab 51 GMX# 51 panitumumab 51 HGS ETR2 51 Poly ICR 51 murine antibodies 51 pralatrexate 51 FluCide 51 investigational antibody 51 shRNA 51 zileuton 51 NPM1 51 intracellular pathways 51 SGLT inhibitors 51 anti angiogenic therapy 51 delipidation 51 Antigen Express 51 JAK inhibitor 51 Factor Receptor 51 therapies ACTs 51 Callisto Pharmaceuticals Inc. 51 mRCC 51 allosteric modulator 51 novel antiviral therapeutics 51 drug GAP #B# 51 hepatitis C HCV 51 lymphoid tumors 51 selective orally bioavailable 51 shRNA libraries 51 Daclizumab 51 nucleotide analogs 51 therapeutic proteins 51 therapeutic peptides 51 SNALP 51 TG# [001] 51 degenerative retinal diseases 51 cells hESCs 51 Tamibarotene 51 galectins 51 Provectus Pharmaceuticals specializes 51 Temsirolimus 51 Fc fusion protein 51 IL #R 51 refractory metastatic